# EDGAR Filing Document

**Accession Number:** 0001665988
**File Stem:** 0001665988-26-000035
**Filing Date:** 2026-6
**Character Count:** 6116
**Document Hash:** 179da9f7e718c808e10ee3cf22e0efc1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001665988-26-000035.hdr.sgml**: 20260604

**ACCESSION NUMBER**: 0001665988-26-000035

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260603

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20260604

**DATE AS OF CHANGE**: 20260604

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Bioventus Inc.
- **CENTRAL INDEX KEY:** 0001665988
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 810980861
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37844
- **FILM NUMBER:** 261063238

**BUSINESS ADDRESS:**
- **STREET 1:** 4721 EMPEROR BOULEVARD, SUITE 100
- **CITY:** DURHAM
- **STATE:** NC
- **ZIP:** 27703
- **BUSINESS PHONE:** (919) 474-6700

**MAIL ADDRESS:**
- **STREET 1:** 4721 EMPEROR BOULEVARD, SUITE 100
- **CITY:** DURHAM
- **STATE:** NC
- **ZIP:** 27703

?xml version='1.0' encoding='ASCII'? bvs-20260603

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

 

**FORM 8-K** 

 

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 3, 2026**

 

**Bioventus Inc.**

**(Exact name of registrant as specified in charter)**

 

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-37844** | **81-0980861** |
| **(State or other jurisdiction**<br>**of incorporation)** | **(Commission**<br>**File Number)** | **(IRS Employer**<br>**Identification Number)** |

---

**4721 Emperor Boulevard, Suite 100**

**Durham, North Carolina 27703**

**(Address of principal executive offices) (Zip Code)**

**Registrant's telephone number, including area code: (919) 474-6700**

**N/A**

**(Former name or former address, if changed since last report)**

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐&nbsp;&nbsp;&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐&nbsp;&nbsp;&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 &nbsp;&nbsp;&nbsp;&nbsp;CFR 240.14d-2(b))

☐&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol(s)** | **Name of each exchange**<br>**on which registered** |
| Class A common Stock, $0.001 par value per share | BVS | The Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

------

**Item 5.07.&nbsp;&nbsp;&nbsp;&nbsp;Submission of Matters to a Vote of Security Holders.**

Bioventus, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "2026 Annual Meeting") on June 3, 2026. A total of 75,279,174 shares (the "Shares") of both Class A common stock and Class B common stock (collectively, the "Common Stock") were present in person or represented by proxy at the 2026 Annual Meeting, representing approximately 90.23% of the outstanding Shares of Common Stock entitled to vote as a single class as of the April 6, 2026 record date.

The following proposals were voted upon at the 2026 Annual Meeting and the final voting results with respect to each such proposal are set forth below.

At the 2026 Annual Meeting, the stockholders elected the following directors to serve on the Company's Board of Directors until the 2027 annual meeting of stockholders and until each such director's respective successor is elected and qualified, or until each such director's death, resignation or removal, based on the following votes:

---

| | | | |
|:---|:---|:---|:---|
| **Nominee** | **For** | **Withheld** | **Broker Non-Votes** |
| William A. Hawkins | 67405961  | 1128994  | 6744219  |
| John A. Bartholdson | 68365980  | 168975  | 6744219  |
| Patrick J. Beyer | 68062114  | 472841  | 6744219  |
| Robert E. Claypoole | 68360467  | 174488  | 6744219  |
| Philip G. Cowdy | 67748512  | 786443  | 6744219  |
| Ajay Dhankhar | 68459149  | 75806  | 6744219  |
| Mary Kay Ladone | 67160936  | 1374019  | 6744219  |
| Michelle McMurry-Heath | 68073685  | 461270  | 6744219  |
| Guido J. Neels | 68049659  | 485296  | 6744219  |
| Guy P. Nohra | 67767651  | 767304  | 6744219  |
| Susan M. Stalnecker | 68060987  | 473968  | 6744219  |
| Martin P. Sutter | 61710650  | 6824305  | 6744219  |

---

The stockholders also ratified the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The vote for such ratification was 75,228,481 Shares for, 5,021 Shares against, 45,672 Shares abstaining, and no broker non-votes.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **BIOVENTUS INC.** | **BIOVENTUS INC.** |
| Date: June 4, 2026 | By: | /s/ Anthony D'Adamio |
|  |  | Anthony D'Adamio<br>Senior Vice President and General Counsel |

---